An update on the long-term safety experience of ustekinumab: results from the psoriasis clinical development program with up to four years of follow-up.
An update on the long-term safety experience of ustekinumab: results from the psoriasis clinical development program with up to four years of follow-up. J Drugs Dermatol. 2012 Mar; 11(3):300-12.